A Study of ZW251 in Participants With Advanced Solid Tumors

Summary

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

Timeline

Start

2025-10-21

Primary completion

2027-09

Completion

2028-05

Drugs

Indications